SEQ
  • Bienvenido a la SEQ
    • Junta Directiva
    • Misión, visión y valores
    • Elecciones para la renovación Junta Directiva de la SEQ 2021
    • Estatutos SEQ
    • Colaboradores
    • Hazte socio
    • Contacto
  • Noticias
    • Cursos
    • Agenda de Congresos
    • Sociedades Científicas
    • Revistas Científicas
  • Actividades
    • Reuniones
    • Congresos
    • Cursos de Formación
  • Revista Española de Quimiopterapia
    • Journal info
    • Advance articles
    • Search an issue
    • Submission guidelines
    • Submit a manuscript
  • Documentos
    • Documentos de Consenso
    • Libros y monografías
    • Revista Infección y Vacunas
    • Informes
    • Declaraciones
    • Base de Datos
    • Otros
      • Curiosidades
      • Narraciones Infecciosas
  • Click to open the search input field Click to open the search input field Buscar
  • Menú Menú
Abstract 2009

Rev Esp Quimioter 2009:22(2):76-82

Multicenter study of in vitro activity of tigecycline in clinical isolates from 30 centers in Spain

J. A. García-Rodríguez y Grupo de Estudio de Sensibilidad Antibiótica 

  

Introduction. In the last years, the increase of antibiotic resistances of grampositive and gramnegative bacteria is an important therapeutic problem. The antimicrobial activity of tigecycline, a novel glycylcycline, was evaluated against 750 bacterial isolates from 30 centers in Spain.

Methods. Multicenter and retrospective study. In 2005, thirty laboratories participated in this study. Data collected in this study included antimicrobial susceptibilities for S.aureus resistant to methicillin (MRSA), ESBL- E. coli or ESBL- K. pneumoniae, E. coli resistant to quinolons (E.coli– QR), Klebsiella spp and E. faecalis. Trains were obtained of the each Hospital´s collection (5 strains of each microorganisms). The susceptibility determinations were performed locally by each laboratory following the standard method usually performed. The tigecycline susceptibility determinations were performed with E/test.

Results. Tigecycline was the most potent agent against MRSA, E. faecalis, E.coli-QR and ESBLs enterobacteriaceae; with MIC50-MIC90 values of: 0.125-0.25 g/ml; 0.125-0.5 g/ml; 0.25-0.75 g/ml and 0.38-1.5 g/ml; respectively.

Conclusions. The results of this study confirm the excellent in vitro activity of tigecycline against gram-positive and gram-negative pathogens, including multirresistant microorganisms.

Key words: Multicenter study. Tigecycline.

Rev Esp Quimioter 2009:22(2):76-82 [pdf] 

28 octubre, 2009/por csanchez
Compartir esta entrada
  • Compartir en Facebook
  • Compartir en X
  • Compartir en LinkedIn
  • Compartir por correo
https://seq.es/wp-content/uploads/2017/10/LOGO-SEQ-800X400.png 0 0 csanchez https://seq.es/wp-content/uploads/2017/10/LOGO-SEQ-800X400.png csanchez2009-10-28 10:44:012009-10-28 10:44:01Rev Esp Quimioter 2009:22(2):76-82

REVISTA ESPAÑOLA DE QUIMIOTERAPIA

  • Journal Info
  • Advance Articles
  • Issues
  • Submission guidelines
  • Submit a manuscript

Contacto

Telf.: 913 94 15 12
Email: [email protected]

Política de privacidad

Aviso Legal
Política de Privacidad
Política de Cookies

Tweets by TwitterDev
© Copyright - Sociedad Española de Quimioterapia - Enfold Theme by Kriesi
  • Link to Facebook
  • Link to X
  • Link to LinkedIn
Link to: Rev Esp Quimioter 2009:22(2):76-82 Link to: Rev Esp Quimioter 2009:22(2):76-82 Rev Esp Quimioter 2009:22(2):76-82 Link to: Rev Esp Quimioter 2009:22(2):83-87 Link to: Rev Esp Quimioter 2009:22(2):83-87 Rev Esp Quimioter 2009:22(2):83-87
Desplazarse hacia arriba Desplazarse hacia arriba Desplazarse hacia arriba